The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Head and Neck Cancer, Squamous Cell Carcinoma of Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
The purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that neoadjuvant use of APG-157 will reduce the tumor burden prior to any definitive therapy to improve the outcomes over current standard of care.
Safety and Efficacy of APG-157 in Head and Neck Cancer
-
VAGLAHS, West Los Angeles, Los Angeles, California, United States, 90073
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States, 33136
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Aveta Biomics, Inc.,
Marilene B Wang, MD, PRINCIPAL_INVESTIGATOR, VA Los Angeles/UCLA
Elizabeth Franzmann, MD, PRINCIPAL_INVESTIGATOR, University of Miami Sylvester Comprehensive Cancer Center
2024-12-31